ABSTRACT

Introduction

Retinal disease treatment delivery is mostly limited to intravitreal injections and slow-release injectable implants due to structural barriers in the eye, and carry associated adverse effects and relatively high treatment burden. The Port Delivery System with ranibizumab (PDS) is a novel drug delivery device that is surgically implanted into the vitreous cavity and allows for continuous release of the anti-vascular endothelial growth factor (anti-VEGF) ranibizumab, eliminating the need for frequent intravitreal injections while maintaining therapeutic intraocular drug levels to control disease activity. Investigations of PDS are summarized in this review.

Areas covered

The most recent reported findings from preliminary studies and phase I–III trials are reviewed. We discuss the ramifications of these studies and the future potential for PDS in the treatment of retinal diseases.

Expert opinion

PDS is a novel drug delivery platform for the treatment of retinal diseases. Currently, the data from the PDS has shown promising efficacy and ability to substantially mitigate treatment burden while effectively generating visual and anatomic outcomes similar to those in patients receiving the standard monthly ranibizumab for neovascular age-related macular degeneration. Further studies are ongoing to investigate this novel drug delivery system in other disease states.

中文翻译：

---

端口传递系统：治疗视网膜疾病的新型药物传递平台

摘要

介绍

由于眼部结构障碍，视网膜疾病治疗主要限于玻璃体内注射和缓释可注射植入物，并伴有相关的不良反应和相对较高的治疗负担。带有雷珠单抗 (PDS) 的 Port Delivery System 是一种新型药物输送装置，通过手术植入玻璃体腔，可连续释放抗血管内皮生长因子 (anti-VEGF) 雷珠单抗，无需频繁玻璃体内注射同时维持治疗性眼内药物水平以控制疾病活动。本综述总结了 PDS 的研究。

覆盖区域

回顾了初步研究和 I-III 期试验的最新报告结果。我们讨论了这些研究的后果以及 PDS 在治疗视网膜疾病方面的未来潜力。

专家意见

PDS是一种用于治疗视网膜疾病的新型给药平台。目前，来自 PDS 的数据显示出有希望的疗效和能力，可显着减轻治疗负担，同时有效地产生类似于接受标准每月雷珠单抗治疗新生血管性年龄相关性黄斑变性的患者的视觉和解剖学结果。正在进行进一步的研究，以在其他疾病状态下研究这种新型药物递送系统。